Myosana Therapeutics is a new biotech company developing novel platform technology for non-viral gene delivery.
Myosana Therapeutics has raised $5.0M in total funding. The most recent round was Seed. The last funding was announced in December 2022.
Myosana Therapeutics's investors include Muscular Dystrophy Association, CureDuchenne Ventures, John Ballantyne, Parent Project Muscular Dystrophy.
Myosana Therapeutics is headquartered in Seattle, United States.
Myosana Therapeutics is a new biotech company developing novel platform technology for non-viral gene delivery.
Myosana Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Myosana Therapeutics — Funding & Investors." VCBacked, December 7, 2022, https://www.vcbacked.co/company/myosana-therapeutics. Accessed October 3, 2026.
VCBacked. (2022). Myosana Therapeutics — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/myosana-therapeutics
{{cite web |title=Myosana Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/myosana-therapeutics |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated